CDK
Los inhibidores de las quinasas dependientes de ciclina (CDK) son compuestos que bloquean la actividad de las CDK, un grupo de quinasas de proteínas que regulan el ciclo celular, la transcripción y otros procesos celulares. Las CDK se activan al unirse a las ciclinas, y su actividad es crucial para la progresión de las células a través de las diferentes fases del ciclo celular. Inhibir las CDK puede detener la división celular, provocando la detención del ciclo celular y la apoptosis, especialmente en células cancerosas donde las CDK a menudo están desreguladas. Los inhibidores de CDK se utilizan ampliamente en la investigación del cáncer y tienen un potencial terapéutico en el tratamiento de varios tipos de cáncer. En CymitQuimica, ofrecemos una selección completa de inhibidores de CDK de alta calidad para apoyar su investigación en el control del ciclo celular, el cáncer y el desarrollo terapéutico.
Se han encontrado 500 productos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Senexin C
CAS:<p>Senexin C is a CDK8/19 inhibitor with anticancer activity.Senexin C inhibits the growth of MV4-11 leukemia cells.</p>Fórmula:C28H27N5OPureza:98.06%Forma y color:SolidPeso molecular:449.55Bisindolylmaleimide X hydrochloride
CAS:<p>Bisindolylmaleimide X hydrochloride (BIM-X hydrochloride) is a potent and selective PKC inhibitor. It is also a potent CDK2 antagonist (IC50: 200 nM).</p>Fórmula:C26H25ClN4O2Pureza:99.23%Forma y color:SolidPeso molecular:460.96Cdc7-IN-7
CAS:<p>Cdc7-IN-7 is a potent inhibitor of Cdc7 kinase.</p>Fórmula:C21H22N4O5Pureza:98.78%Forma y color:SolidPeso molecular:410.42CDK9-IN-23
CAS:<p>CDK9-IN-23 (Example 4) is a potent inhibitor of CDK9, exhibiting an IC50 value of less than 20 nM [1].</p>Fórmula:C22H25ClN4O3Pureza:98%Forma y color:SolidPeso molecular:428.91Senexin A hydrochloride
CAS:<p>Senexin A hydrochloride functions as a selective inhibitor of CDK8/19, with an IC 50 of 280 nM for CDK8, and specifically inhibits p21-induced transcription without affecting other biological effects of p21. Additionally, it suppresses CMV-GFP induction and the stimulatory activity of the consensus NF-κB-dependent promoters [1] [2].</p>Fórmula:C17H15ClN4Forma y color:SolidPeso molecular:310.78CDK9-IN-19
CAS:<p>CDK9-IN-19: Potent CDK9 inhibitor, anti-cancer, moderate pharmacokinetics, low hERG impact, effective in AML research.</p>Fórmula:C26H22F2N4O5Forma y color:SolidPeso molecular:508.47Riviciclib
CAS:<p>Riviciclib, a CDK inhibitor (CDK9/T1, CDK4/D1, CDK1/B), has IC50s: 20, 63, 79 nM respectively, and fights cisplatin-resistant tumors.</p>Fórmula:C21H20ClNO5Pureza:98%Forma y color:SolidPeso molecular:401.84ML 315 hydrochloride
CAS:<p>ML 315, a selective dual inhibitor targeting CDK (Cyclin-Dependent Kinase) and DYRK (Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase) with IC50 values of 68 nM and 282 nM, respectively, is utilized in research pertaining to cancer and neurological diseases [1].</p>Fórmula:C18H14Cl3N3O2Forma y color:SolidPeso molecular:410.682(S)-Cdc7-IN-18
CAS:<p>'(S)-Cdc7-IN-18 from patent WO2020239107A1 inhibits CDC7, curbing MCM2 and tumor growth.'</p>Fórmula:C19H21N5OSForma y color:SolidPeso molecular:367.47CDK7-IN-25
CAS:<p>CDK7-IN-25 (CY-16-1) is a potent CDK7 inhibitor with an IC50 value of less than 1nM, utilized in cancer research [1].</p>Fórmula:C33H32N6O3Pureza:98%Forma y color:SolidPeso molecular:560.65Inixaciclib
CAS:<p>Inixaciclib is a potent CDK inhibitor, can be used to research anticancer.</p>Fórmula:C26H30F2N6OForma y color:SolidPeso molecular:480.55SZ-015268
CAS:<p>SZ-015268: CDK7 inhibitor, IC50=23.56 nM; hinders HCC70, OVCAR-3, HCT116, HCC1806 cell growth; strong anti-tumor effect.</p>Fórmula:C25H38N8O3Forma y color:SolidPeso molecular:498.62CDK4/6-IN-15
CAS:<p>CDK4/6-IN-15: Oral, selective CDK4/6 inhibitor, halts cancer cell growth, G1 arrest, suppresses Rb phosphorylation.</p>Fórmula:C21H27FN8SForma y color:SolidPeso molecular:442.56CDK4/6-IN-17
CAS:<p>CDK4/6-IN-17 (compound 12) is an orally bioavailable inhibitor of CDK4/6, demonstrating potent activity with IC50 values between 10-100 nM in BE(2) cells.</p>Fórmula:C27H28F4N8Pureza:98%Forma y color:SolidPeso molecular:540.56Cdc7-IN-12
CAS:<p>Cdc7-IN-12, a sub-1 nM CDC7 inhibitor, may aid cancer research; hinders COLO205 cell growth (IC50: 100-1000 nM).</p>Fórmula:C16H14N2O2SForma y color:SolidPeso molecular:298.36Xylocydine
CAS:<p>Xylocydine is a novel Cdk inhibitor that induces apoptosis in HCC, suppresses tumor growth, and is non-toxic to other tissues.</p>Fórmula:C12H14BrN5O5Forma y color:SolidPeso molecular:388.17CF53
CAS:<p>CF53: potent, selective oral BET inhibitor; Ki <1 nM, Kd 2.2 nM, IC50 2 nM for BRD4 BD1; high affinity for BRD2/3/4/BRDT; effective anti-tumor agent.</p>Fórmula:C24H25N7O2Pureza:99.72%Forma y color:SolidPeso molecular:443.5Cdk1/2 Inhibitor III
CAS:<p>Cdk1/2 Inhibitor III is a selective Cdk1/2 inhibitor with an IC50 value of 2.1 μM against CDK1/cyclin B.</p>Fórmula:C15H13F2N7O2S2Pureza:99.07%Forma y color:SolidPeso molecular:425.44(R)-Simurosertib
CAS:<p>(R)-Simurosertib ((R)-TAK-931) is an inhibitor of the ATP-competitive cell division cycle 7 (CDC7) kinase.</p>Fórmula:C17H19N5OSPureza:99.89%Forma y color:SolidPeso molecular:341.43XY028-140
CAS:<p>XY028-140 is a selective CDK4/6 inhibitor and degrader, acting via PROTAC with ligands for Cereblon and CDK in cancer cells.</p>Fórmula:C39H40N10O7Pureza:98.59%Forma y color:SolidPeso molecular:760.8Debio-0123
CAS:<p>Debio-0123: potent, specific oral WEE1 inhibitor; IC50 in low nanomolar; boosts DNA damage & Carboplatin's anti-cancer effects.</p>Fórmula:C26H28Cl2N6OPureza:99.93%Forma y color:SolidPeso molecular:511.45AZD4573
CAS:<p>AZD4573 is an effective and selective CDK9 inhibitor (IC50: <4 nM). It enables transient target engagement for the treatment of hematologic malignancies.</p>Fórmula:C22H28ClN5O2Pureza:99% - 99.51%Forma y color:SolidPeso molecular:429.94PPA-037
CAS:<p>PPA-037 is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). It induces the degradation of Cyclin K, thereby enhancing antiproliferative effects on tumor cells. PPA-037 holds potential for use in cancer research.</p>Fórmula:C25H27N7Forma y color:SolidPeso molecular:425.53CDK1-IN-7
CAS:<p>CDK1-IN-7 (compound M7) is a potent CDK1 inhibitor. It effectively suppresses the proliferation and migration of HCT116 and Lovo cells, making it a valuable tool for colorectal cancer research.</p>Fórmula:C23H19ClN4O3Forma y color:SolidPeso molecular:434.88YL-1-9
CAS:<p>YL-1-9 is an inhibitor that prevents the degradation of p53 by MDM2 through tight binding to the crucial hydrophobic pocket of MDM2. It can induce cell cycle arrest and apoptosis in breast cancer cells [1].</p>Fórmula:C22H23F3N2O3Forma y color:SolidPeso molecular:420.425CDK9 autophagic degrader 1
CAS:<p>CDK9 autophagic degrader 1 (Compound 28) is an ATTEC degrader used to target and degrade CDK9, also impacting the levels of its associated Cyclin T1. At a concentration of 100 nM, it exhibits over 80% inhibition of CDK9.</p>Fórmula:C34H39N7O4S2Forma y color:SolidPeso molecular:673.848CDK9-IN-11
CAS:<p>CDK9-IN-11 is a potent CDK9 inhibitor that is the ligand for the PROTAC CDK9 Degrader-1 [1].</p>Fórmula:C20H25N3O4Pureza:98%Forma y color:SolidPeso molecular:371.43RGB-286638
CAS:<p>RGB-286638 inhibits multiple CDKs and GSK-3β, TAK1, Jak2, MEK1 with IC50s as low as 1-54 nM.</p>Fórmula:C29H37Cl2N7O4Forma y color:SolidPeso molecular:618.55Cimpuciclib tosylate
CAS:<p>Cimpuciclib tosylate, a selective CDK4 inhibitor (IC50: 0.49 nM), exhibits anti-tumor activity.</p>Fórmula:C37H43FN8O4SForma y color:SolidPeso molecular:714.85CDK2/4-IN-2
CAS:<p>CDK2/4-IN-2 (compound 56) serves as a dual inhibitor for CDK2 and CDK4, exhibiting an IC50 of less than 100 nM. It is applicable in cancer research.</p>Fórmula:C18H20F3N7O3S2Forma y color:SolidPeso molecular:503.52CDK2 degrader 4
CAS:<p>CDK2 degrader4 (compound 104) is a potent degrader of CDK2, showing promise for cancer research applications.</p>Fórmula:C23H26ClN3O5Forma y color:SolidPeso molecular:459.923CDK8-IN-9
<p>CDK8-IN-9, potent CDK8 inhibitor (IC50: 48.6 nM), curbs tumor growth, useful for colorectal cancer research.</p>Forma y color:SolidPROTAC CDK12/13 Degrader-1
<p>PROTAC CDK12/13 Degrader-1 (7f) selectively degrades CDK12/13 at nanomolar potency, targeting breast cancer.</p>Forma y color:SolidCDK7-IN-33
CAS:<p>CDK7-IN-33 (Compound 148) is a CDK7 inhibitor with a Ki value of 21.75 nM. It suppresses the proliferation of A549 cells expressing CDK7WT, with a pIC50 of 7.37.</p>Fórmula:C29H36N6O4SForma y color:SolidPeso molecular:564.699CDK/HDAC-IN-1
<p>CDK/HDAC-IN-1 inhibits CDK2/4/6 & HDAC6 with IC50s: 60.9, 276, 27.2, and 128.6 nM respectively.</p>Fórmula:C20H18N4O4Forma y color:SolidPeso molecular:378.38LZ9
CAS:<p>LZ9 is an ATP-competitive inhibitor of CDK1 and CDK2, with potential applications in colorectal cancer (CRC) research.</p>Fórmula:C17H11F3N4O2Forma y color:SolidPeso molecular:360.29CDK1-IN-3
<p>CDK1-IN-3 is a selective inhibitor targeting CDK1 (36.8 nM), CDK2 (305.17 nM), CDK5 (369.37 nM); used in cancer research.</p>Fórmula:C28H25ClF3N5O2Forma y color:SolidPeso molecular:555.98Haspin-IN-2
CAS:<p>Haspin-IN-2 is a potent haspin inhibitor (IC50: 50 nM) and also inhibits CLK1 (IC50: 445 nM) and DYRK1A (IC50: 917 nM).</p>Fórmula:C12H8N4O3Forma y color:SolidPeso molecular:256.22CDK4-IN-1
CAS:<p>CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50</p>Fórmula:C22H29ClN8Pureza:98%Forma y color:SolidPeso molecular:440.97Cdc7-IN-10
CAS:<p>Cdc7-IN-10 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in studies of proliferative diseases.</p>Fórmula:C20H22F2N4O2SForma y color:SolidPeso molecular:420.48DDO-6079
CAS:<p>DDO-6079 is an efficient CDC37 inhibitor. It suppresses the HSP90-CDC37 and CDC37-CDK4/6 chaperone complexes by binding to an allosteric site on CDC37. Additionally, DDO-6079 reduces the thermal stability of CDK6.</p>Fórmula:C18H13ClN2O3Forma y color:SolidPeso molecular:340.76CDK7-IN-18
CAS:<p>CDK7-IN-18: potent, pyrimidine-based CDK7 inhibitor with cancer research potential.</p>Fórmula:C22H24F3N7OSForma y color:SolidPeso molecular:491.53CLK1/2-IN-1
CAS:<p>CLK1/2-IN-1 is a CLK1 and CLK2 inhibitor and it also inhibits SRPK1 and SRPK2.</p>Fórmula:C21H20F3N7OPureza:98%Forma y color:SolidPeso molecular:443.42TMX-3013
CAS:<p>TMX-3013 is a CDK inhibitor that targets multiple cyclin-dependent kinases, specifically suppressing the activity of CDK1, CDK2, CDK4, CDK5, and CDK6 with IC50 values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM respectively. Additionally, TMX-3013 is utilized in the synthesis of PROTACs, which use polyethylene glycol (PEG) as a linker and Thalidomide as the CRBN-recruiting arm.</p>Fórmula:C17H14BrFN6O3SForma y color:SolidPeso molecular:481.3CDK2-IN-8
<p>CDK2-IN-8 is a potent CDK2 inhibitor (IC50= 1.74 μM). CDK2-IN-8 exhibits antiproliferative activity. CDK2-IN-8 can be used for the research of melanoma.</p>Fórmula:C22H25N5O3Forma y color:SolidPeso molecular:407.47CDK2-IN-31
CAS:<p>CDK2-IN-31 (compound I-125A) is an inhibitor of CDK2 and is utilized in cancer research.</p>Fórmula:C37H52N6O5Forma y color:SolidPeso molecular:660.85CDK12/13 ligand 1
CAS:<p>ALK-IN-29 (compound 4c) exhibits notable inhibitory activity against tyrosine kinases such as ALK, CDK2/CyclinE1, and FAK, with the strongest inhibition observed against ALK kinase, showing a 40.63% inhibition rate at a concentration of 10 μM. ALK-IN-29 is useful for cancer research.</p>Fórmula:C26H26BrN5OForma y color:SolidPeso molecular:504.42CDK1-IN-5
<p>CDK1-IN-5 is a selective inhibitor for CDK1 (IC50: 42.19 nM), CDK2, CDK5, halting cancer cell growth.</p>Fórmula:C27H26ClN5OSForma y color:SolidPeso molecular:504.05CDK5-IN-2
CAS:<p>CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor that acts on CDK5/p25 (IC50: 0.2 nM) and CDK2/CycA (IC50: 23 nM).</p>Fórmula:C29H28FN5OForma y color:SolidPeso molecular:481.56CDK8-IN-14
CAS:<p>CDK8-IN-14 (compound 12) effectively inhibits CDK8, demonstrating an IC50 of 39.2 nM, and exhibits potent anti-AML cell proliferation effects, with a GC50 value of 0.02±0.01μM in MOLM-13 cells and 0.03±0.01μM in MV4-11 cells [1].</p>Fórmula:C18H13N3O2Forma y color:SolidPeso molecular:303.31GSK3-IN-10
CAS:<p>GSK3-IN-10 (Compound 4) is a multi-target inhibitor primarily affecting GSK3α and GSK3β with IC50 values of 1.0 nM and 2.0 nM, respectively. It inhibits the activation of β-catenin, enhances neuronal survival, and provides protective effects against endoplasmic reticulum stress.</p>Fórmula:C17H18F2N4O3Forma y color:SolidPeso molecular:364.347DB18
CAS:<p>DB18 serves as a potent, selective inhibitor of CDC2-like kinases (CLKs), exhibiting IC50 values between 10-30 nM for CLK1, CLK2, and CLK4. Additionally, it possesses anti-tumor activity [1].</p>Fórmula:C24H18ClN7O3Forma y color:SolidPeso molecular:487.9(R)-Atuveciclib
CAS:<p>Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb / CDK9 inhibitor that inhibits CDK9 / CycT1 with an IC 50 of 13 nM [1].</p>Fórmula:C18H18FN5O2SPureza:98%Forma y color:SolidPeso molecular:387.43CDK2-IN-18
CAS:<p>CDK2-IN-18 (compound 8q) serves as a powerful inhibitor of CDK 2/E and CDK 4/D1, showing IC50 values of 8 nM and 46 nM, respectively. It effectively inhibits tumor cell proliferation [1].</p>Fórmula:C21H23N7O2SForma y color:SolidPeso molecular:437.52CDK2 degrader 6
CAS:<p>CDK2 degrader6 (compound 6) is an orally active CDK2 degrader with a DC50 of 46.5 nM, and is applicable in breast cancer research.</p>Fórmula:C23H22F5N5O3Forma y color:SolidPeso molecular:511.44INX-315
CAS:<p>INX-315 is an orally active, selective CDK2 inhibitor that induces cell cycle arrest and senescence in solid tumours, suppresses E2F target gene expression.</p>Fórmula:C19H21N7O3SPureza:99.88%Forma y color:SolidPeso molecular:427.48CDK9-IN-13
<p>CDK9-IN-13 is a potent and selective CDK inhibitor (IC50<3 nM). CDK9-IN-13 has a very short half-life in rodents.</p>Fórmula:C27H35N5O2Forma y color:SolidPeso molecular:461.6CDK8-IN-11 hydrochloride
<p>CDK8-IN-11 HCl: potent, selective CDK8 inhibitor (IC50: 46 nM), blocks WNT/β-catenin pathway, used in colon cancer research.</p>Fórmula:C19H16ClF3N4O2Forma y color:SolidPeso molecular:424.8CDK9-IN-38
CAS:<p>CDK9-IN-38 (compound 14) is a CDK9 inhibitor with IC50 values of 1.2 nM for wild-type CDK9 and 3.3 nM for the L156F mutant. It effectively inhibits tumor growth both in vitro and in vivo.</p>Fórmula:C22H23N5O3SForma y color:SolidPeso molecular:437.515CDK4/6-IN-13
CAS:<p>Compounds 10B and 10C: potent cdk4/6 inhibitors with low nM activity, great antiproliferative effects, excellent metabolism, and good pharmacokinetics.</p>Fórmula:C25H29N7OForma y color:SolidPeso molecular:443.54CLK1/4-IN-1
<p>CLK1/4-IN-1 inhibits Clk1/4 (IC50: 9.7/6.6 nM), curbing T24 cell growth (GI50: 1.1 μM). Potential cancer research tool.</p>Fórmula:C18H14ClNO4SForma y color:SolidPeso molecular:375.83Anticancer agent 29
<p>Compound E/Z-6f, anticancer, IC50: CDK2 (0.054 μM), CDK1 (0.127 μM), CDK4 (0.129 μM), CDK6 (0.396 μM).</p>Fórmula:C22H15ClFNOForma y color:SolidPeso molecular:363.81CDK4/6-IN-24
CAS:<p>CDK4/6-IN-24 (Compound A) is an inhibitor of CDK4/6 with broad-spectrum antitumor activity. It can effectively inhibit various cancer cells, exhibiting an IC50 in the submicromolar range.</p>Fórmula:C32H41N7O3Forma y color:SolidPeso molecular:571.713Zeltociclib
CAS:<p>Zeltociclib is an inhibitor of cyclin-dependent kinases (CDKs) with anti-tumor properties.</p>Fórmula:C18H20F3N4O2PForma y color:SolidPeso molecular:412.346Cdc7-IN-18
CAS:<p>Cdc7-IN-18 (1-2) inhibits CDC7 enzyme (IC50: 1.29 nM) and COLO205 cell proliferation (IC50: 53.62 nM).</p>Fórmula:C19H21N5OSForma y color:SolidPeso molecular:367.47Cdc7-IN-11
CAS:<p>Cdc7-IN-11 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in the study of proliferative diseases.</p>Fórmula:C20H22F2N4O2SForma y color:SolidPeso molecular:420.48CDK2-IN-40
CAS:<p>CDK9-IN-40 is an inhibitor of CDK2 (Cyclin-dependent kinase 2). It effectively inhibits CDK2/Cyclin E1, with an IC50 of ≤ 10 nM.</p>Fórmula:C16H21N7O2Forma y color:SolidPeso molecular:343.384CDK2-IN-30
CAS:<p>CDK2-IN-30 (Formula (I)) is a CDK2 inhibitor with an IC50 of ≤20 nM, utilized primarily in tumor research.</p>Fórmula:C18H25N7O3SForma y color:SolidPeso molecular:419.50CDK1-IN-6
<p>CDK1-IN-6 (Ligand 3) is an effective inhibitor of CDK1 and shows potential for use in cancer research.</p>Fórmula:C21H22N4OForma y color:SolidPeso molecular:346.43CDDD11-8
CAS:<p>CDDD11-8 is an orally administered, highly potent and selective CDK9 and FLT3-ITD inhibitor, with K i values of 8 nM and 13 nM, respectively. It effectively reduces the proliferation of leukemia cell lines, showing particular efficacy against those with the FLT3-ITD mutation [1] [2].</p>Fórmula:C24H26N6Forma y color:SolidPeso molecular:398.50CDK2-IN-39
CAS:<p>CDK2-IN-39 (compound 4) is a CDK2 inhibitor.</p>Fórmula:C14H15N3O4SForma y color:SolidPeso molecular:321.352CDK4/9-IN-1
CAS:<p>CDK4/9-IN-1 (Compound 29) is a selective dual inhibitor of CDK4 and CDK9, exhibiting IC50 values of 23 nM and 12 nM, respectively. It holds potential for use in cancer research.</p>Fórmula:C22H34N6O2Forma y color:SolidPeso molecular:414.544P162-0948
CAS:<p>P162-0948 is a selective CDK8 inhibitor with an IC50 value of 50.4 nM. It reduces cell migration and the expression of EMT-related proteins in the A549 human alveolar epithelial cell line. Furthermore, P162-0948 decreases Smad phosphorylation, indicating disruption of the TGF-β/Smad signaling pathway, making it a promising compound for pulmonary fibrosis research.</p>Fórmula:C20H15FN4O2Forma y color:SolidPeso molecular:362.357DS96432529
<p>DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.</p>Fórmula:C18H26N4O3SForma y color:SoildPeso molecular:378.49CTX-712
CAS:<p>CTX-712 is a potent inhibitor of cdc2-like kinase ( CLK ). CTX-712 inhibits inhibits cancer survival and cancer cell growth.</p>Fórmula:C19H17FN8O2Forma y color:SolidPeso molecular:408.39CDK7/12-IN-1
CAS:<p>CDK7/12-IN-1 is a selective CDK7 (IC50: 3 nM) and CDK12 (IC50: 277 nM) inhibitor, effective against tumor growth.</p>Fórmula:C25H34N8OForma y color:SolidPeso molecular:462.59Haspin-IN-1
<p>Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.</p>Fórmula:C12H8N4O2SForma y color:SolidPeso molecular:272.28CDK7-IN-17
CAS:<p>CDK7-IN-17, a pyrimidine-based CDK7 inhibitor, shows promise for various cancers, especially with abnormal transcription.</p>Fórmula:C24H26F3N6OPForma y color:SolidPeso molecular:502.47CDK1-IN-4
<p>CDK1-IN-4 inhibits CDK1 (IC50: 44.52 nM), CDK2/CDK5 less potently, impacts cell cycle, used in cancer studies.</p>Fórmula:C26H24ClN5SForma y color:SolidPeso molecular:474.02PKMYT1-IN-7
CAS:<p>PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM for PKMYT1 and 0.06 μM for pCDK1. It inhibits the phosphorylation of CDK1 at T14 and Y15 sites and exhibits anticancer activity both in vitro and in vivo.</p>Fórmula:C17H18FN5O3Forma y color:SolidPeso molecular:359.355CDK7-IN-31
CAS:<p>CDK7-IN-31 (compound 13) is an effective and orally active inhibitor of cyclin-dependent kinase 7 (CDK7) with a dissociation constant (Kd) of 0.18 nM. This compound exhibits anticancer activity.</p>Fórmula:C27H32F5N6O2PForma y color:SolidPeso molecular:598.55Protein kinase inhibitor 11
CAS:<p>Protein kinase inhibitor 11 (Compound I-96) is an agent that inhibits the activity of PIM-1, CDK-2, GSK-3, and SRC. It shows potential for research in cancer, autoimmune diseases, and neurodegenerative disorders.</p>Fórmula:C21H18FN5O2SForma y color:SolidPeso molecular:423.463Cdc7-IN-8
CAS:<p>Cdc7-IN-8, inhibits Cdc7 kinase, key in DNA replication, and is promising for cancer research. (WO2021032170A1)</p>Fórmula:C19H21N5O2Forma y color:SolidPeso molecular:351.40CDK6-IN-1
CAS:<p>CDK6-IN-1 (compound 4i) is an inhibitor of CDK6 that suppresses cell growth and induces cell cycle arrest at the G1 phase.</p>Fórmula:C30H23N5Forma y color:SolidPeso molecular:453.54Anticancer agent 30
<p>Anticancer agent 30 (6f-Z), a 3-arylidene-2-oxindole, selectively inhibits CDK2, showing potent anticancer potential.</p>Fórmula:C22H15ClFNOForma y color:SolidPeso molecular:363.81Protein Kinase Inhibitor 12
CAS:<p>Protein Kinase Inhibitor 12 (compound 1-91) is protein kinase inhibitor,PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases.</p>Fórmula:C14H14N4OSPureza:98.06%Forma y color:SolidPeso molecular:286.35YKL-1-116
CAS:<p>YKL-1-116 is an effective, selective, and covalent CDK7 inhibitor.</p>Fórmula:C34H38N8O3Pureza:98%Forma y color:SolidPeso molecular:606.72CDK9/PARP-IN-1
CAS:<p>CDK9/PARP-IN-1 (compound 37) is an inhibitor of CDK9 and PARP. It demonstrates IC50 values of 118 nM for CDK9 and 107 nM for PARP1. This compound exhibits a broad-spectrum anti-proliferative effect across various cancer cell lines.</p>Fórmula:C38H34F2N8O3Forma y color:SolidPeso molecular:688.725Protein kinase inhibitor 13
CAS:<p>Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.</p>Fórmula:C19H20FN5OSForma y color:SolidPeso molecular:385.458Cdc7-IN-19
CAS:<p>Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC 50 of 1.49 nM [1].</p>Fórmula:C19H21N5O2Forma y color:SolidPeso molecular:351.40CDK8-IN-5
CAS:<p>CDK8-IN-5: potent CDK8 inhibitor, IC50=72 nM, boosts IL-10 by 43%, may aid inflammatory bowel disease research.</p>Fórmula:C26H22N2O4Forma y color:SolidPeso molecular:426.46CDK4/6-IN-3
CAS:<p>CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.</p>Fórmula:C25H31FN8Pureza:98%Forma y color:SolidPeso molecular:462.57SGC-CLK-1
CAS:<p>SGC-CLK-1 is a potent and selective inhibitor of Cdc2-like kinases CLK1, CLK2, and CLK4. It effectively inhibits the growth of melanoma and glioblastoma cells.</p>Fórmula:C19H15F3N6O2Forma y color:SolidPeso molecular:416.36p38α inhibitor 9
CAS:<p>p38α inhibitor9 (Compound 2015) is a p38α inhibitor that effectively blocks the enzyme activity of p38α, with an IC50 of less than 20 nM. It inhibits MK2T334 phosphorylation and activates Cdc25b and Cdc25c while inactivating Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy, and DNA damage. Additionally, p38α inhibitor9 can suppress colorectal cancer (CRC) metastasis.</p>Fórmula:C27H24FN3O3Forma y color:SolidPeso molecular:457.496GFB-12811
CAS:<p>GFB-12811 is an orally active, selective, and potent CDK5 inhibitor, used in the study of autosomal dominant polycystic kidney disease.</p>Fórmula:C22H23F4N5OPureza:98.88%Forma y color:SolidPeso molecular:449.44LY3143921 hydrate
CAS:<p>LY3143921 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor with broad in vitro anticancer activity [1].</p>Fórmula:C16H14FN5O2Pureza:98.43%Forma y color:SolidPeso molecular:327.31Tanuxiciclib
CAS:<p>Tanuxiciclib is a cyclin dependent kinase (CDK) inhibitor, specifically designed to interfere with cell cycle progression by inhibiting the activity of CDKs, which are crucial regulators of cell division.</p>Fórmula:C15H13FN6OForma y color:SolidPeso molecular:312.308GSK-3/CDK5/CDK2-IN-1
CAS:<p>GSK-3/CDK5/CDK2-IN-1 is an imidazole derivative compound that inhibits cdk5, cdk2, and GSK-3.it has demonstrated applications in cancer research and the study of neurodegenerative diseases [1].</p>Fórmula:C21H22N4O2Forma y color:SolidPeso molecular:362.433Tibremciclib
CAS:<p>Tibremciclib is a cyclin-dependent kinase 4 (CDK4) inhibitor that exhibits antineoplastic properties [1].</p>Fórmula:C28H32F2N8Pureza:98%Forma y color:SolidPeso molecular:518.6YK-2168
CAS:<p>YK-2168 is a differentiated selective inhibitor of CDK9.</p>Fórmula:C16H18ClN5Forma y color:SolidPeso molecular:315.80Ref: TM-T200769
Producto descatalogado
